Details of the Drug

General Information of Drug (ID: DMNKLZM)

Drug Name
TgAAG76
Synonyms RAAV 2/2.hRPE65p.hRPE65; AAV RPE65 gene therapy (RPE65-mediated blindness), Targeted Genetics/University of London/Moorfields
Indication
Disease Entry ICD 11 Status REF
Blindness 9D90 Phase 1/2 [1]
Cross-matching ID
DrugBank ID
DB18421
TTD ID
D04FSD

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinal pigment epithelium protein (RPE65) TTBOH16 RPE65_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00643747) Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis. U.S. National Institutes of Health.
2 tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. Curr Opin Mol Ther. 2010 Aug;12(4):471-7.